215 related articles for article (PubMed ID: 10027001)
21. Roles of FHIT and WWOX fragile genes in cancer.
Iliopoulos D; Guler G; Han SY; Druck T; Ottey M; McCorkell KA; Huebner K
Cancer Lett; 2006 Jan; 232(1):27-36. PubMed ID: 16225988
[TBL] [Abstract][Full Text] [Related]
22. Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact.
Wang L; Darling J; Zhang JS; Qian CP; Hartmann L; Conover C; Jenkins R; Smith DI
Oncogene; 1998 Feb; 16(5):635-42. PubMed ID: 9482109
[TBL] [Abstract][Full Text] [Related]
23. Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma.
Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen RL; Gao JX; He G
Ann Clin Lab Sci; 2010; 40(3):267-72. PubMed ID: 20689140
[TBL] [Abstract][Full Text] [Related]
24. Initiation of genome instability and preneoplastic processes through loss of Fhit expression.
Saldivar JC; Miuma S; Bene J; Hosseini SA; Shibata H; Sun J; Wheeler LJ; Mathews CK; Huebner K
PLoS Genet; 2012; 8(11):e1003077. PubMed ID: 23209436
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms shaping the mutational landscape of the FRA3B/FHIT-deficient cancer genome.
Saldivar JC; Park D
Genes Chromosomes Cancer; 2019 May; 58(5):317-323. PubMed ID: 30242938
[TBL] [Abstract][Full Text] [Related]
26. Structure and expression of the human FHIT gene in normal and tumor cells.
Druck T; Hadaczek P; Fu TB; Ohta M; Siprashvili Z; Baffa R; Negrini M; Kastury K; Veronese ML; Rosen D; Rothstein J; McCue P; Cotticelli MG; Inoue H; Croce CM; Huebner K
Cancer Res; 1997 Feb; 57(3):504-12. PubMed ID: 9012482
[TBL] [Abstract][Full Text] [Related]
27. Instability at chromosomal fragile sites.
Glover TW
Recent Results Cancer Res; 1998; 154():185-99. PubMed ID: 10027000
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines.
Tamura G; Sakata K; Nishizuka S; Maesawa C; Suzuki Y; Iwaya T; Terashima M; Saito K; Satodate R
Genes Chromosomes Cancer; 1997 Sep; 20(1):98-102. PubMed ID: 9290961
[TBL] [Abstract][Full Text] [Related]
29. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type.
Muller CY; O'Boyle JD; Fong KM; Wistuba II; Biesterveld E; Ahmadian M; Miller DS; Gazdar AF; Minna JD
J Natl Cancer Inst; 1998 Mar; 90(6):433-9. PubMed ID: 9521167
[TBL] [Abstract][Full Text] [Related]
30. Common chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B loss-induced global genome instability.
Hosseini SA; Horton S; Saldivar JC; Miuma S; Stampfer MR; Heerema NA; Huebner K
Genes Chromosomes Cancer; 2013 Nov; 52(11):1017-29. PubMed ID: 23929738
[TBL] [Abstract][Full Text] [Related]
31. Expression of aberrant functional and nonfunctional transcripts of the FHIT gene in Burkitt's lymphomas.
Ferrer M; López-Borges S; Lazo PA
Mol Carcinog; 1999 May; 25(1):55-63. PubMed ID: 10331745
[TBL] [Abstract][Full Text] [Related]
32. A Fhit-ing role in the DNA damage checkpoint response.
Ishii H; Wang Y; Huebner K
Cell Cycle; 2007 May; 6(9):1044-8. PubMed ID: 17457056
[TBL] [Abstract][Full Text] [Related]
33. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos.
Nelson HH; Wiencke JK; Gunn L; Wain JC; Christiani DC; Kelsey KT
Cancer Res; 1998 May; 58(9):1804-7. PubMed ID: 9581816
[TBL] [Abstract][Full Text] [Related]
34. A novel approach to simultaneously scan genes at fragile sites.
Willem P; Brown J; Schouten J
BMC Cancer; 2006 Aug; 6():205. PubMed ID: 16895604
[TBL] [Abstract][Full Text] [Related]
35. Alterations of common chromosome fragile sites in hematopoietic malignancies.
Ishii H; Furukawa Y
Int J Hematol; 2004 Apr; 79(3):238-42. PubMed ID: 15168591
[TBL] [Abstract][Full Text] [Related]
36. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
[TBL] [Abstract][Full Text] [Related]
37. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
Turner BC; Ottey M; Zimonjic DB; Potoczek M; Hauck WW; Pequignot E; Keck-Waggoner CL; Sevignani C; Aldaz CM; McCue PA; Palazzo J; Huebner K; Popescu NC
Cancer Res; 2002 Jul; 62(14):4054-60. PubMed ID: 12124341
[TBL] [Abstract][Full Text] [Related]
38. Alteration of the fragile histidine triad gene early in carcinogenesis: an update.
Ishii H; Ozawa K; Furukawa Y
J Exp Ther Oncol; 2003; 3(6):291-6. PubMed ID: 14678517
[TBL] [Abstract][Full Text] [Related]
39. Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses.
Ishii H; Vecchione A; Fong LY; Zanesi N; Trapasso F; Furukawa Y; Baffa R; Huebner K; Croce CM
Curr Gene Ther; 2004 Mar; 4(1):53-63. PubMed ID: 15032614
[TBL] [Abstract][Full Text] [Related]
40. Direct correlation between FRA3B expression and cigarette smoking.
Stein CK; Glover TW; Palmer JL; Glisson BS
Genes Chromosomes Cancer; 2002 Jul; 34(3):333-40. PubMed ID: 12007194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
